Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has been granted FDA approval for its amlodipine besylate tablets for the treatment of chronic stable angina and vasospastic angina.
Subscribe to our email newsletter
The approval covers the drug in 2.5mg, 5mg and 10mg doses. Shipment of the product will begin shortly.
Teva’s tablets are the AB-rated generic equivalent of Pfizer’s Norvasc tablets. Mylan, which also markets a generic version, has sued the FDA arguing that its 180-day exclusivity blocks other final approvals until September, 2007.
Total annual sales of the drug are approximately $2.8 billion for the 12 months ended March 31, 2007, based on IMS sales data.